Race for Ebola Vaccine Gains Steam.

0
214
Illustration of a container of Ebola vaccine
Illustration of a container of Ebola vaccine

Scientists globally are in a time crunch race to get a vaccine for the Bundibugyo strain of the Ebola virus that has so far caused 4,400 deaths in parts of the DR Congo, Uganda and Kenya.

The current outbreak of the viral hemorrhagic fever began in D.R.C on May 15, 2026, with the central African state accounting for the greatest disease burden with 9,400 cases while Uganda has reported 20 cases and Kenya 8.

The World Health Organization has confirmed that clinical trial for a potential vaccine is set to begin by the end of this month.

The vaccine, Ervebo, is currently being used as a vaccine against the Zaire strain of the Ebola virus. The clinical trials will seek to establish if the vaccine can also protect against Bundibugyo that is responsible for the current outbreak.

“Ervebo is approved for use against the Zaire strain of Ebola. It is safe and highly effective against this virus, but its protection against Bundibugyo has not been established.” Emanuele Capobianco, the Director of Global Health Security at The Global Vaccine Alliance popularly known as Gavi has said.

The current stockpile of the vaccine stands at 500,000 doses, with 70,000 having been released to the DRC as part of the ongoing studies.

Among those who have received the jabs are health workers at the frontline in the fight against the outbreak.

Capobiamco has also confirmed that other vaccines that are specifically tailor-made for The Bundibugyo strain of Ebola are in development.

Two of the most promising are being developed by Oxford University in partnership with India’s Serum Institute of India and another being worked on by American biotechnology company Moderna.

“We are expecting the results of their phase 1 trials later in October. They will provide data on their safety and their ability to stimulate the immune system.”

“If the results are positive, phase 2 and 3 trials may begin on larger populations. These will last several months and will make it possible to evaluate their efficacy. If all goes well, a rollout could take place in the first half of 2027.”

Kenya currently reported 8 cases of the virus and 1 death. The death is that of the first patient, a Kenyan who travelled back home from the DRC and succumbed to the deadly viral fever while admitted at the Nairobi Hospital.

All the other 7 cases are directly linked to the first one with The Minstry of Health dispelling fear of a communal spread of the virus.

LEAVE A REPLY

Please enter your comment!
Please enter your name here